The API manufacturer said the facility is one of four scheduled modules at its commercial peptide manufacturing site. With the foundational infrastructure for the second module already in place, Neuland expects to begin work ahead of the original timeline once customer requirements are finalised.
“Configuration, instrumentation and capacity are currently being defined in close collaboration with the customer whose projects will anchor the expanded capability,” the company said.
7,000-litre reactor capacity
The newly operational module has a total reactor capacity of 7,000 litres, comprising 750 litres of solid-phase peptide synthesis (SPPS) and 6,250 litres of liquid-phase peptide synthesis (LPPS).The facility can support customer programmes ranging from small-scale to multi-kilogram quantities for complete peptide APIs, including complex and long-chain peptides, as well as commercial-scale production of crude peptides.
The SPPS and LPPS reactors are housed in separate suites, allowing parallel operations. The module is also supported by three DAC columns and two lyophilisers with capacities of 100 litres and 200 litres.
Neuland invested $30 million in the first module and said further investments in subsequent modules will be aligned with new customer requirements.
Second module capacity
The second module is planned to have a total reactor capacity of up to 18,000 litres. It will include three 5,000-litre LPPS reactors, either a 1,000-litre or 2,000-litre SPPS reactor, and smaller reactors of up to 1,000 litres.
Neuland said this configuration will allow it to support a broad range of peptide programmes and production scales.
The company also said the range of partner indications is expanding beyond obesity and metabolic disease, with oncology emerging as an active area of early-stage development.
“As peptide pipelines expand, a growing number of biotech companies are struggling to access capable outsourced development and commercial manufacturing capacity,” Neuland said.
Neuland CEO and Managing Director Saharsh Davuluri said the company is planning capacity with a longer-term demand outlook.
“Our goal is to ensure we have the capacity to meet customer demand not just over the next 24 months, but over the next decade, as we deepen our strategic partnerships with leading pharma and biotech companies,” Davuluri said.
Module one is supported by a team of nearly 212 peptide experts, the company said.
Davuluri also noted that the latest development follows strong growth for Neuland’s CDMO business, with revenues rising 116% in its most recent quarterly results, driven primarily by increased commercial contracts and a growing number of clinical projects.
Shares of Neuland Laboratories are trading 2.4% lower on Tuesday at ₹22,965. The stock is witnessing some profit booking at higher levels, having risen 53% so far this year.
Also read: Here’s why Afcons Infra share price surged as much as 20% on Tuesday
